Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Onesource shares fall up to 7% on semaglutide supply delay, guidance cut from key client
Shares of OneSource Specialty Pharma declined 7.4% to hit an intraday low of ₹1,506.1 apiece on Friday. The stock has since, recovered from the lows of the day.
Aegis Logistics among 4 stocks that closed below VWAP
Four Nifty500 stocks, Balkrishna Industries, Aegis Logistics, PhysicsWallah and OneSource Specialty Pharma, closed over 3% below VWAP, highlighting bearish sentiment and weakening price momentum.
Poly Medicure among 4 stocks that closed below VWAP
Four Nifty500 stocks, Poly Medicure, Aditya Birla Real Estate, Siemens Energy India, and Onesource Specialty Pharma, closed over 2% below their VWAP on July 3, indicating potential bearish momentum and heightened selling pressure, according to technical scan data.
USFDA inspects OneSource's sterile product division facility at Bengaluru
The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
AI-led global earnings pressure India; opportunities in power, pharma: Conrad Saldanha
Neuberger Berman MD & Portfolio Manager Conrad Saldanha discusses why AI-driven earnings growth in the US, Korea and Taiwan continues to attract capital, shares his outlook on India, and highlights opportunities in power infrastructure, airports, specialty pharma and select financials.
Onesource Industries & Ventures reports standalone net loss of Rs 1.99 crore in the March 2026 quarter
Sales rise 2.20% to Rs 19.02 crore
Margin pressure, slower growth outlook may cap upside for Sun Pharma stock
Sun Pharma reported strong revenue and profit growth in the March quarter, but EBITDA margins faced pressure from increased investments and lower milestone income. The company anticipates range-bound margins and moderating revenue growth in FY27, driven by specialty launches and R&D spending. Domestic formulations remain robust, while US segment recovery is expected to be gradual.
Anupam Rasayan to acquire up to 43 pc stake in Bliss GVS Pharma for around Rs 1,369 cr
Specialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with an open offer for an additional 26%. This strategic move aims to strengthen Anupam Rasayan's presence across the pharmaceutical value chain, from key starting materials to finished dosage formulations.
Five Stocks To Buy: Aurobindo Pharma, Tata Communications, Graphite India And More | May 18, 2026
Top picks include pharma majors Aurobindo Pharma and OneSource Specialty Pharma, agrochemical player Sumitomo Chemical India, telecom giant Tata Communications, and industrial manufacturing firm Graphite India.
Onesource Specialty Pharma gets government nod for Unit II expansion project
The company said Unit II is a flagship facility of the company and the proposed expansion represents a significant step in its growth strategy to enhance manufacturing capacities for servicing global partners.
Zydus Lifesciences acquires US pharma firm Assertio for $166 million
In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166.40 million deal to acquire Assertio Holdings. The purchase includes Assertio’s essential cancer treatment, Rolvedon, and offers Zydus a rich commercial network to elevate its oncology initiatives.